Status:
COMPLETED
Atrial Fibrillation Characterization on Paroxysmal and Persistent Patients
Lead Sponsor:
Felipe Atienza
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Background and Hypothesis: Atrial Fibrillation (AF) treatment strategies have limitations. The efficacy of the procedure depends in several factors such as age, AF duration, atrial diameter and atrial...
Detailed Description
The main objective of this project is to develop and validate new biomarkers based on a pre-existing methodology for the non-invasive identification of the mechanisms that are responsible for the main...
Eligibility Criteria
Inclusion
- Patients with paroxysmal or persistent AF symptomatic and refractory to at least one antiarrhythmic medication arriving in sinus rhythm to the electrophysiology laboratory.
- Patients must be able and willing to provide written informed consent to participate in the study.
- Prior anticoagulation for\> 4 weeks or transesophageal echocardiogram excluding intracardiac thrombi.
Exclusion
- Patients with inadequate anticoagulation levels, left atrial thrombus, tumor, or another abnormality which precludes catheter introduction on TEE prior to the procedure.
- Patients with moderate-to-severe mitral regurgitation.
- Patients with contraindications to systemic anticoagulation with heparin or coumadin.
- Patients who are or may potentially be pregnant.
- Current enrollment in another investigational drug or device study.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT05343923
Start Date
June 1 2021
End Date
December 31 2023
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General Universitario Gregorio Marañón
Madrid, Spain, 28007